Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Titanium-prepared platelet-rich fibrin (T-PRF) is an autologous, third-generation platelet concentrate used primarily in regenerative dentistry and oral surgery. Developed as an advancement over traditional leukocyte- and platelet-rich fibrin (L-PRF), T-PRF is produced by centrifuging a patient's blood in medical-grade titanium tubes rather than glass or plastic. The titanium surface is thought to be more biocompatible and a more potent activator of the coagulation cascade, resulting in a fibrin network with thicker fibers and a more organized structure. This dense fibrin matrix serves as a biological scaffold that provides a sustained release of essential growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors promote angiogenesis, cell migration, and tissue healing. T-PRF is utilized to enhance wound healing and bone regeneration in procedures such as gingivectomy, sinus lifts, and alveolar ridge preservation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on titanium-prepared platelet-rich fibrin.